All In Biotech

Drug Trial Radar · NCT00384930

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Last checked: Nov 19, 2026Latest source record: Sep 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,058 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,058

Actual

Start

Aug 2006

Primary completion

Oct 2007

Study completion Oct 2008

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
ICOS Corporation
First posted
Oct 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including lower urinary tract symptoms.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • tadalafilDrug

    2.5 mg tadalafil tablet by mouth once a day for twelve weeks.

  • tadalafilDrug

    5 mg tadalafil tablet by mouth once a day for twelve weeks.

  • tadalafilDrug

    10 mg tadalafil tablet by mouth once a day for twelve weeks.

  • tadalafilDrug

    20 mg tadalafil tablet by mouth once a day for twelve weeks.

  • placeboDrug

    Placebo tablet taken by mouth one a day for twelve weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary AnalysisTime frame: Baseline and 12 weeks
  2. Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive AnalysisTime frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

    Greenwood, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.